Aviceda Therapeutics has launched biotech financing in 2025 with a $207.5m raise to advance its lead drug for geographic atrophy, a sight-threatening disease, into pivotal trials.
The Series C round, co-led by Omega Funds and TCGX, will support the ongoing phase 2/3 SIGLEC trial of AVD-104 for geographic atrophy linked to age-related macular degeneration.
The trial is expected to deliver results in the second half of the year, with funding also allocated to a phase 3 programme if progress stays on track.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
The funding round also saw participation from investment firms including Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, and Digitalis Ventures.
Source: Pharmaphorum
Can’t stop reading? Read more
How private equity can build resilience in a world gone unpredictable
How private equity can build resilience in a world gone unpredictable Resilience isn’t a buzzword...
HarbourView acquires Issa Rae’s ColorCreative to scale diverse media platform
HarbourView acquires Issa Rae’s ColorCreative to scale diverse media platform HarbourView Equity...
KKR acquires Australia’s Zenith Energy in $1.1bn deal to target energy transition growth
KKR acquires Australia’s Zenith Energy in $1.1bn deal to target energy transition growth KKR has...